Skip to main content

REVIEW article

Front. Med.
Sec. Gastroenterology
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1457218
This article is part of the Research Topic Gut Microbiota and Gastrointestinal Disorders - Volume II View all 6 articles

Cross-Talk Between Macrophages and Gut Microbiota in Inflammatory Bowel Disease: A Dynamic Interplay Influencing Pathogenesis and Therapy

Provisionally accepted
Shiyang Ning Shiyang Ning 1Zhe Zhang Zhe Zhang 1Zhou Chuan Zhou Chuan 1Binbin Wang Binbin Wang 1Zhanju Liu Zhanju Liu 1,2*Baisui Feng Baisui Feng 1*
  • 1 Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  • 2 Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China

The final, formatted version of the article will be published soon.

    Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease (CD), is a group of chronic immune-mediated gastrointestinal disorders. The etiology of IBD is multifactorial, involving genetic susceptibility, environmental factors, and a complex interplay between the gut microbiota and the host's immune system. Intestinal resident macrophages play an important role in the pathogenesis and progress of IBD, as well as in maintaining intestinal homeostasis and facilitating tissue repair. This review delves into the intricate relationship between intestinal macrophages and gut microbiota, highlighting their pivotal roles in IBD pathogenesis. We discuss the impact of macrophage dysregulation and the consequent polarization of different phenotypes on intestinal inflammation. Furthermore, we explore the compositional and functional alterations in gut microbiota associated with IBD, including the emerging significance of fungal and viral components. This review also examines the effects of current therapeutic strategies, such as 5-aminosalicylic acid (5-ASA), antibiotics, steroids, immunomodulators, and biologics, on gut microbiota and macrophage function. We underscore the potential of fecal microbiota transplantation (FMT) and probiotics as innovative approaches to modulate the gut microbiome in IBD. The aim is to provide insights into the development of novel therapies targeting the gut microbiota and macrophages to improve IBD management.

    Keywords: ： IBD1, gut microbiota2, macrophage3, SCFAs4, TRP5, Sencondary bile

    Received: 30 Jun 2024; Accepted: 28 Aug 2024.

    Copyright: © 2024 Ning, Zhang, Chuan, Wang, Liu and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Zhanju Liu, Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China
    Baisui Feng, Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.